Khushali Parekh
Nirma University of Science and Technology
8 Papers
12 Citations
Khushali Parekh is an academic researcher from Nirma University of Science and Technology. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Emerging Nanomedicines for the Treatment of Atopic Dermatitis.
TL;DR: In this article, a review of current development and emerging nanomedicines for effective treatment of Atopic Dermatitis (AD) is presented, which provides an insight incidences associated with pathophysiology of AD and challenges with existing treatments of AD.
Two dimensional carbon based nanocomposites as multimodal therapeutic and diagnostic platform: A biomedical and toxicological perspective.
TL;DR: This work intends to provide a thorough, up-to-date holistic discussion on correlation of breakthroughs with their biomedical applications and illustrate how to utilize these breakthroughs to address long-standing challenges in the clinical translation of nanomedicines.
33
Tacrolimus encapsulated mesoporous silica nanoparticles embedded hydrogel for the treatment of atopic dermatitis
Khushali Parekh,Kartik Hariharan,Zhi Qu,Prarthana V. Rewatkar,Yuxue Cao,Moniruzzaman,Preeti Pandey,Amirali Popat,Tejal Mehta +8 more
TL;DR: In this paper, mesoporous silica nanoparticles (MSNs) were synthesized using sol gel technique and surface functionalized using amino (-NH2+) and phosphonate (-PO3-) groups.
25
Surface-Modified PLGA Nanoparticles for Targeted Drug Delivery to Neurons
Tejal Mehta,Neha Shah,Khushali Parekh,Namdev Dhas,Jayvadan K. Patel +4 more
- 01 Jan 2019
TL;DR: Current non-nanoparticle strategies are reviewed, such as delivery of drugs through the permeable BBB under pathological conditions and using noninvasive techniques to enhance brain drug uptake.
18
Skin cancer therapeutics: nano-drug delivery vectors—present and beyond
TL;DR: In this article, a panoramic view is presented on the etiology, therapeutic options, and emerging drug delivery modalities for skin cancer, where a wide array of drug carriers with very distinguishing characteristics and target specificity are evaluated.
11